How a Drug Gets Its Label and Its Approved Indication

A drug label is the official, regulator-approved account of what a medicine is, who it is for, and how it should be used. Its central promise is the approved indication: the specific disease, population, and conditions of use for which a regulator has concluded, based on the evidence submitted, that the benefits outweigh the risks. That indication is not written by the marketing team and it is not a summary of everything the drug can plausibly do. It is drawn tightly around the trials that were actually run. That single fact explains why "on-label" and "off-label" matter, and why two drugs with similar biology can carry very different labels.

The label is a legal document, not a brochure

In the United States the label is formally the Prescribing Information, often called the USPI or Full Prescribing Information. It is part of the New Drug Application or Biologics License Application, and once approved it becomes the legally binding statement of the conditions under which the drug may be marketed. The European equivalent is the Summary of Product Characteristics. These documents follow a fixed structure for a reason: a clinician reading any modern label knows exactly where to find dosing, contraindications, warnings, adverse reactions, and the data behind them.

The opening section, Indications and Usage, is the one everyone reads first and the one that is fought over most. Under the governing regulations it must state the approved indication concisely and may only include uses supported by substantial evidence of safety and effectiveness. That phrase, substantial evidence, is the hinge of the whole system. It is a legal standard, and the entire clinical development program exists to meet it.

The indication is defined by the evidence you submit

Here is the part that surprises people outside development. A regulator does not approve a molecule in the abstract. It approves a claim, and the claim can be no broader than the studies that support it.

If a sponsor runs its pivotal trials in adults with a specific condition, at a specific dose, on a specific background therapy, the indication will describe adults with that condition, at that dose, in that setting. Studying only adults usually means no pediatric claim. Excluding patients with significant kidney impairment usually means the label says so, or carries a dosing caveat. The chosen primary endpoint shapes the words the regulator is willing to grant. An indication is, in effect, a compressed description of the trial population and design.

This is why label negotiation is one of the most consequential parts of a submission. Two teams can read the same dataset and argue for a wider or narrower sentence. The regulator's job is to ensure the sentence does not promise more than the data can carry. Having worked on global development programs, including the GLP-1 and insulin portfolio at Novo Nordisk, I can say the indication is often settled late, after the efficacy and safety picture is fully assembled, because it has to reflect what was demonstrated rather than what was hoped.

Why the evidence has to be trustworthy first

None of this works unless the data are credible. That is the role of Good Clinical Practice, the international ethical and scientific standard for designing, running, and reporting trials. The framework was refreshed in 2025: the ICH E6(R3) guideline reached its final step on 6 January 2025, with the European Medicines Agency applying it from 23 July 2025 and the FDA publishing it on 9 September 2025. The revision leans into quality-by-design, risk-based oversight, and modern data governance, reflecting decentralized and technology-enabled trials. Alongside it sit ICH E8 on general trial considerations and ICH E9 on statistical principles, including how a study defines the question it is trying to answer. The logic is linear: sound design and conduct produce trustworthy evidence, and trustworthy evidence is what a regulator will let you put on the label.

On-label and off-label

Once the indication exists, it draws a line. Prescribing a drug for the approved population and use is on-label. Prescribing it for a different disease, a different age group, or a different dose is off-label.

Off-label use is legal in most systems and is often clinically reasonable. A physician may have good grounds, sometimes strong published evidence, for using an approved drug outside its labeled indication, and in fields such as oncology and pediatrics this is common. The distinction is not that off-label use is forbidden. It is that the regulator has not reviewed and endorsed that specific use, so the formal weighing of benefit against risk that the label represents has not been done for it. The evidence may exist, but it has not passed through the approval gate.

The asymmetry sits with the manufacturer. A clinician may prescribe off-label; a company generally may not promote off-label. It cannot market the drug for uses the label does not cover, because the label defines the boundary of what has been proven to the regulator's standard. This is why sponsors invest in additional trials to expand an indication rather than relying on real-world use. New population, new claim, new evidence.

Reading a label with this in mind

For a clinician, the practical takeaways are concrete. The Indications and Usage section tells you what was proven, not the full range of what the drug might do. The trial population described there tells you how far you are extrapolating when your patient differs from it. Warnings and contraindications are earned from observed data, not theoretical caution. And a narrow indication is not a weak drug; it usually reflects a focused development program with room to grow as more studies are completed. Some pathways, such as orphan-drug designations for rare diseases, exist precisely to make well-defined narrow indications viable.

The label, then, is the visible output of an invisible process: a protocol, a population, endpoints, statistics, and a standard of evidence, compressed into a few paragraphs a prescriber can act on. Once you see that the indication describes the evidence rather than the molecule, the whole system becomes legible, and the on-label versus off-label distinction stops being bureaucratic and starts being informative.

This article is educational and is not medical advice; prescribing decisions should be made by a qualified clinician for the individual patient.